Eunsik Lee
Overview
Explore the profile of Eunsik Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1717
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al.
J Clin Oncol
. 2023 Apr;
41(11):1957-1964.
PMID: 37018920
Purpose: Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety...
2.
Eoh Y, Lee E, Park S
Appl Res Qual Life
. 2022 Jul;
17(6):3579-3593.
PMID: 35813891
Supplementary Information: The online version contains supplementary material available at 10.1007/s11482-022-10080-w.
3.
Suh J, Jung J, Jeong C, Lee S, Lee E, Ku J, et al.
Investig Clin Urol
. 2020 May;
61(3):269-276.
PMID: 32377602
Purpose: The clinical behavior of prostate cancer differs by race and ethnicity; however, data on the Korean population are scarce. We assessed the long-term oncologic outcomes of clinically localized prostate...
4.
Lee J, Lee S, Ho J, Youn J, Byun S, Lee E
Biosci Biotechnol Biochem
. 2019 Aug;
83(12):2265-2271.
PMID: 31362565
As standard second-line regimen has not been established for patients who are refractory to or relapse with cisplatin-based chemotherapy, an effective class of novel chemotherapeutic agents is needed for cisplatin-resistant...
5.
Ryu H, Jin H, Ho J, Bae J, Lee E, Lee S, et al.
Biol Pharm Bull
. 2019 Jan;
42(1):66-72.
PMID: 30606990
Cisplatin chemotherapy is the standard treatment for metastatic urothelial carcinoma. Although there are second-line chemotherapeutic agents approved by the U.S. Food and Drug Administration (FDA) such as those targeting programmed...
6.
Lee S, Kim K, Ho J, Jin H, Byun S, Lee E
Oncol Lett
. 2017 Sep;
14(3):3011-3018.
PMID: 28928839
Docetaxel-based chemotherapy is the standard treatment for metastatic castration-resistant prostate cancer (CRPC). However, a number of patients with metastatic CRPC are refractory to docetaxel or develop docetaxel resistance. The underlying...
7.
Byun S, Hong S, Lee S, Kook H, Lee E, Kim H, et al.
Investig Clin Urol
. 2016 Mar;
57(1):50-7.
PMID: 26966726
Purpose: The purpose of this article is to report establishment of the 1st Web-based database (DB) system to collect renal cell carcinoma (RCC) data in Korea. Materials And Methods: The...
8.
Kim M, Ku J, Kwak C, Kim H, Lee E, Keam B, et al.
PLoS One
. 2015 Jul;
10(7):e0133371.
PMID: 26200905
Preclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to gemcitabine and cisplatin,...
9.
Eom K, Ha S, Lee E, Kwak C, Lee S
Radiat Oncol J
. 2015 Jan;
32(4):247-55.
PMID: 25568853
Purpose: To determine whether neoadjuvant androgen deprivation therapy (NADT) improves clinical outcomes in patients with prostate cancer treated with definitive radiotherapy. Materials And Methods: We retrospectively reviewed medical records of...
10.
Lee Y, Lee S, Ho J, Byun S, Hong S, Lee S, et al.
Oncol Rep
. 2014 Sep;
32(5):1803-8.
PMID: 25175462
Cisplatin-based chemotherapy is the first‑line treatment for metastatic urothelial cell carcinoma. However, for cisplatin‑resistant cases, no chemotherapeutic agent has been established as a standard of treatment. This study aimed to...